Member Info for TrekMadone

Yep we sure are, been here since 16p my only regret selling 22k on the way up but hey these guys have actually caught up with and surpassed the hype. I didn’t think that that was the case before but now I am a buyer here again in the new isa wrapper when it comes as NR and team are delivering. We’ll see the same at DCTA there is plenty of room in this market and soon the easiest way for the big chemical Cos to get in will be to buy these minnows. I’m not here for that as I think there is much more value longer term for shareholders as an independent co but I don’t think we’ll be able to defend it especially if there are competing bids and NR may just be given a offer he can’t refuse. Trek on tea leaves.

Massive? Surely there is a bigger word than that for “We foresee potential opportunities for partnerships in sportswear, city wear, jeans, workwear, but also in tires and asphalts” and of course not to mention the environmental services like grafysorber, conductors for batteries, medical inks etc etc I mean just how many pairs of jeans and sports gear are there in the US that want a smart computer linked to their apparel. How many miles of tarmac subject to extremes of temperatures. Just how does that fit in with Trumps Keynsian infrastructure spend. Mmm graphite Mexico wall with build in smart sensors built to last..there’s a thought. This stuff is coming into concrete near you soon....All to much for Directa to cope with? Na look at the model...

Innovative and Patented technology that’s Directa Plus then the heavy lifting through collaboration with Dr Patrick Soon Shiong’s Nant empire which has the tech, production and financial capabilities. A supply network and more production that’s from Patrickks contacts and of course lobbying to feed the loop back for more work = more Royalties for Directa if we are still around by then. Trek, humongous!

Hi Brynjon, agree with what you say but DCTA was a very rare tip at 50p. An opportunity ahead of news from all that was in the public domain. First time for me in 15 years of investing in AIM I have ever put tea leaves together so timely. GLA, I'll be back soon.. Mystic Trek

Well done to all you sell on news guys with your profits. There is much much more to come though. £1 is only like £60m MCAP enjoy the view from the sidelines. Trek if only! Lol!

Hi RobinHood69, yes as you say it’s sector related and VRS could become the next billionaires tech toy. This was on Proactive today re DCTA. There catching me up!

Patrick Soon-Shiong: The biotech billionaire with a 19% stake in Directa Plus
Share 15:20 05 Feb 2019
Soon-Shiong’s investment in Directa Plus means he is the third overseas billionaire in as many months to take a sizeable stake in an AIM company
patrick soon shiong
Soon-Shiong (middle) made his money in biotech, but has been investing heavily into tech recently
Patrick Soon-Shiong is the latest billionaire to take a liking to an AIM company after taking a 19% stake in graphene specialist Directa Plus PLC (LON:DCTA).

But who is the man dubbed ‘America’s richest doctor’?

The 66-year-old was born and raised in apartheid South Africa. After earning medical degrees in Johannesburg and Vancouver, he moved to Los Angeles in the eighties where he built a successful career as a surgeon.

READ: Directa Plus notified of big share transactions

It was in 1991 that he began his journey into the financial super elite when he developed cancer drug Abraxane.

He folded the treatment into a generic drug firm he bought and later named American Pharmaceutical Partners. The venture didn’t convince everyone on Wall Street, though, and it soon became a target for short-sellers.

But 14 years later, in 2005, Soon-Shiong received a huge boost when Abraxane was approved by the US Food and Drug Administration.

Net worth of US$8bn

He eventually split APP into two and sold the generics division to German firm Fresenius in 2008 for US$4.6bn. Two years later he sold the other side of the business Abraxis Bioscience, which included Abraxane, to US giant Celgene for US$4.3bn.

At the time of the sales, Soon-Shiong owned around 80% of each of the companies. His estimated net worth, according to Forbes, is around US$8bn.

Since then he has used his wealth to set up other ventures, including California-based NantWorks, from which he has spun off two publicly traded companies – cancer-testing company NantHealth and immunotherapy developer NantKwest.

Neither has fared particularly well since listing and Soon-Shiong has had to deny allegations that funds from his charitable foundation have been used to drive sales.

Recent tech investments

The LA resident has sought investments outside of the biotech arena in recent times, though, and last year he bought the LA Times newspaper along with a handful of regional titles for US$500mln.

He has also been promoting his NantEnergy firm, which has developed a zinc-air rechargeable battery that the billionaire hopes will eventually replace the lithium battery.His interest in innovative tech helps to explain his investment in Directa Plus – an AIM-listed company that is using the ‘wonder material’ graphene to make everything from clothes to tyres.
https://www.proactiveinvestors.co.uk/companies/news/214021/patrick-soon-shiong-the-biotech-bill

This is more like it.....was in Biotech section.

Patrick Soon-Shiong: The biotech billionaire with a 19% stake in Directa Plus
Share
15:20 05 Feb 2019
Soon-Shiong’s investment in Directa Plus means he is the third overseas billionaire in as many months to take a sizeable stake in an AIM company
patrick soon shiong
Soon-Shiong (middle) made his money in biotech, but has been investing heavily into tech recently
Patrick Soon-Shiong is the latest billionaire to take a liking to an AIM company after taking a 19% stake in graphene specialist Directa Plus PLC (LON:DCTA).

But who is the man dubbed ‘America’s richest doctor’?

The 66-year-old was born and raised in apartheid South Africa. After earning medical degrees in Johannesburg and Vancouver, he moved to Los Angeles in the eighties where he built a successful career as a surgeon.

READ: Directa Plus notified of big share transactions

It was in 1991 that he began his journey into the financial super elite when he developed cancer drug Abraxane.

He folded the treatment into a generic drug firm he bought and later named American Pharmaceutical Partners. The venture didn’t convince everyone on Wall Street, though, and it soon became a target for short-sellers.

But 14 years later, in 2005, Soon-Shiong received a huge boost when Abraxane was approved by the US Food and Drug Administration.

Net worth of US$8bn

He eventually split APP into two and sold the generics division to German firm Fresenius in 2008 for US$4.6bn. Two years later he sold the other side of the business, Abraxis Bioscience, which included Abraxane, to US giant Celgene for US$4.3bn.

At the time of the sales, Soon-Shiong owned around 80% of each of the companies. His estimated net worth, according to Forbes, is around US$8bn.

Since then he has used his wealth to set up other ventures, including California-based NantWorks, from which he has spun off two publicly traded companies – cancer-testing company NantHealth and immunotherapy developer NantKwest.

Neither has fared particularly well since listing and Soon-Shiong has had to deny allegations that funds from his charitable foundation have been used to drive sales.

Recent tech investments

The LA resident has sought investments outside of the biotech arena in recent times, though, and last year he bought the LA Times newspaper along with a handful of regional titles for US$500mln.

He has also been promoting his NantEnergy firm, which has developed a zinc-air rechargeable battery that the billionaire hopes will eventually replace the lithium battery.

His interest in innovative tech helps to explain his investment in Directa Plus – an AIM-listed company that is using the ‘wonder material’ graphene to make everything from clothes to tyres.

https://www.proactiveinvestors.co.uk/companies/news/214021/patrick-soon-shiong-the-biotech-billionaire-with-a-19-stake-in-directa-plus-214021.html

Trek,, news junkie!

MM must hold min 1500 see market size...
https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary/GB00BSM98843GBGBXASQ1.html?lang=en

Ps really psd at that proactive newscast as not fully loaded here yet and it’s so difficult to buy. I was waiting for VOD divi to clear so I could sell the rest and pile in some more. Sds law trying to save a tenner in dealing cost! Anyways 70p tomorrow. Trek and hopefully a tight spread!

There we go pretty much played down IMO, a billionaire buying 20% of a £30m MCAP Co.. oh well I guess no perspective but at least they have put the facts out there....

Directa Plus notified of big share transactions, with 19% of the graphene products developer changing hands
Share 17:00 31 Jan 2019 After the market close, Directa Plus reported that Indaco Venture Partners SGR, Italy’s largest independent venture capital asset management firm, had sold a holding of 8.06% in the group
Graphene On Wednesday afternoon, Directa Plus announced that American billionaire Patrick Soon-Shiong now holds 18.95% of the company Directa Plus PLC (LON:DCTA) revealed in a filing after the market close on Thursday that it was notified that Indaco Venture Partners SGR, Italy’s largest independent venture capital asset management firm, had sold a holding of 8.06% in the graphene products developer.

The announcement followed similar filings late on Wednesday that showed three US investors had all sold their holdings in the company in transactions on Monday, with William Cate, Paul Calarco, and Robert Mercuri disposing of stakes totalling 3.69% each in the company.

READ: Placing and open offer brings in £3.45mln for Directa Plus

On Wednesday afternoon, Directa Plus also announced that American billionaire Patrick Soon-Shiong now holds 18.95% of the graphene company following a deal on Friday last week.

Soon-Shiong, a California-based investor, is the owner of the Los Angeles Times and The San Diego Union-Tribune and has been a minority owner of the LA Lakers basketball team since 2010.

His stake in Directa Plus is held via his holding company, Nant Capital. In September 2018, a Soon-Shiong company, NantEnergy announced the development of a zinc air-breathing battery which broke the US$100 per kilowatt-hour cost barrier.

Back in January, Directa Plus announced that it had raised a total of £3.45mln through a share placing and open offer to fund an investment drive to grow in its markets.

The firm raised around £3.15mln through the placing of 6.3mln new shares at 50p each in December.

The company said it raised a further £0.30mln through an open offer at the same price, with Directa Plus’s chief executive Giulio Cesareo and chairman Sir Peter Middleton among the directors taking part.

https://www.proactiveinvestors.co.uk/companies/news/213994/directa-plus-notified-of-big-share-transactions-with-19-of-the-graphene-products-developer-changing-hands-213994.html.

Trek, in the news. Sshh!

No it’s not billionaire buying. Those three trades today has pushed it up 13%. Look at my last post and the orders on LSE see the -5444 and the 2 x 5444. That is because like I said before the trades were released I cancelled a limit order because it wouldn’t go through at 60p. The reason for that is because I was pipped by the 5k buy so it had not chance so I cancelled my limit order hence the -5444 and took a chance on straight to broker and the order was filled at 62p. Another buy for 3614 followed quickly after and they had to pay 64p. Look guys imo we don’t have long to load up here it’s going to blast through 70p soon to 90p with 70p support. download chart and look at the ridges from May 17. Now they have bookbuild out way and investor I think we are climbing back out of the trough. Trek my view on technicals fwiw, wtfdik, DYOR whooopeee!

Just got another 5444, won’t show yet. Tried an age to buy couldn’t get 60p took a chance on straight to broker and got 62p then the ask went up to 65p right away after. Trek, mmm what else can I sell to keep piling in here? shhhhh.

Yes may be OTC deal which would make sense, I didn’t notice volume spike though but may still have been on open market. Wish they’d just get their heads together and transfer whatever number of shares at a mutual price as then I think we’d be off and Abcam could get in one bed! Trek

Stonking results. I wonder if they may toe the line a little early and reel in a hurricane. SP trurning? Trek blow us away.

Everyone wants a cut. Trek

Thanks NoMark I will follow up. Trek

Yep spread been going out to deter buyers coz MM are so short of stock andthey will have a job to match trades. We are over due an update on Sartec and grafysorber. With POO higher and oil infrastructure stocks doing well news or a deal there could send this crazy. I think after deep water the industry and lobbyists will eventually insist grafysorber or similar is a mandatory on site safety requirement. Trek oh, there is no similar!

Yep there we have it, holdings RNS, woody selling probably to cover up abismal performance elsewhere. I thought the results weren't bad. Trek sticking with the numbers as value will out.

Rising when there are more indicative sells than buys. Good sign imo that someone has an order in. Trek

The graphene potential market is huge. There is enough room for a hundred VRS’s and DCTA’s and that would only scratch the manufacturing surface. The amazing thing is there is to my knowledge only two serious players that produce graphene. Others piggy back (HAYD, AGM etc). VRS business model of renting out the patented IT is the way forward. It’s the same principle as Optibiotix (OPTI) use in the biotech space and is the way forward. Both VRS and OPTI have had to work really hard at selling the patented tech. Just look at the help from DTI VRS has had. The b2b progress is what has built the SP. Now whilst VRS have a first mover advantage in China; DCTA with Dr Patrick Soon Shiongs multi billion $ network will build a similar model in the US. He could also fund production through his Nant empire oh and financing if he so wishes so he doesn’t need primary bid (nothing wrong with that) or the DTI, US equivalent as he knows Trump so fewer hoops to navigate. Directa in collaboration with Nant will imo move very quickly in the US. Space race graphene style! My money is on a future NASDAQ listing as the US investors are very tech savvy and very hungry for this sort of Co. Trek. Disclaimer I hold DCTA, VRS and OPTI and loving it!

I am staggered not at the news but at the SP under reaction. Long may it continue. I am desperately trying to get funds ready for the next ISA window and none of it is going on this dog! Trek woof woof!

Good news but note fierce competition. Also ‘The agreement strongly supports Gfinity's financial targets for this financial year and offers additional revenue opportunities through ticket sales and commercial rights.’. This imo won’t be enough based on previous event revenues. I am sitting on sidelines until after next imo imminent raise. Trek, GL to holders.